Scarica l'app Stockscreener
115.63
3.15%
3.53
Dopo l'orario di chiusura:
118.00
2.37
+2.05%
Precedente Chiudi:
$112.10
Aprire:
$113.17
Volume 24 ore:
672.76K
Relative Volume:
0.87
Capitalizzazione di mercato:
$7.93B
Reddito:
$217.17M
Utile/perdita netta:
$-202.68M
Rapporto P/E:
-50.21
EPS:
-2.3028
Flusso di cassa netto:
$-156.63M
1 W Prestazione:
+16.50%
1M Prestazione:
+1.02%
6M Prestazione:
+11.60%
1 anno Prestazione:
+25.03%
Intervallo 1D:
$111.69
$116.18
Intervallo di 1 settimana:
$97.56
$116.18
Portata 52W:
$74.50
$122.20
Rhythm Pharmaceuticals Inc Stock (RYTM) Company Profile
Nome
Rhythm Pharmaceuticals Inc
Settore
Industria
Telefono
857-264-4280
Indirizzo
222 BERKELEY STREET, BOSTON, MA
Compare RYTM vs VRTX, REGN, ARGX, RVMD, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RYTM
Rhythm Pharmaceuticals Inc
|
115.63 | 7.28B | 217.17M | -202.68M | -156.63M | -2.3028 |
VRTX
Vertex Pharmaceuticals Inc
|
496.07 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
784.36 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
865.04 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
205.15 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
348.27 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Rhythm Pharmaceuticals Inc Stock (RYTM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-19 | Iniziato | RBC Capital Mkts | Outperform |
| 2025-11-25 | Iniziato | Citigroup | Buy |
| 2025-11-05 | Downgrade | Oppenheimer | Outperform → Perform |
| 2025-07-10 | Iniziato | Goldman | Buy |
| 2025-07-07 | Iniziato | Leerink Partners | Outperform |
| 2025-04-07 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2025-03-05 | Ripresa | Stifel | Buy |
| 2025-01-02 | Iniziato | Jefferies | Buy |
| 2024-12-20 | Iniziato | Oppenheimer | Outperform |
| 2024-10-21 | Iniziato | Guggenheim | Buy |
| 2024-09-18 | Iniziato | H.C. Wainwright | Buy |
| 2024-09-17 | Iniziato | JMP Securities | Mkt Outperform |
| 2024-05-08 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-12-19 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2023-08-01 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2023-01-18 | Ripresa | Canaccord Genuity | Buy |
| 2022-08-08 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-08-05 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2022-06-17 | Reiterato | Needham | Buy |
| 2022-03-02 | Ripresa | Stifel | Buy |
| 2022-02-17 | Aggiornamento | Ladenburg Thalmann | Neutral → Buy |
| 2021-12-08 | Iniziato | Wells Fargo | Overweight |
| 2021-11-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-14 | Ripresa | Goldman | Neutral |
| 2021-08-04 | Downgrade | BofA Securities | Neutral → Underperform |
| 2021-08-04 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| 2020-11-30 | Downgrade | BofA Securities | Buy → Neutral |
| 2020-01-08 | Iniziato | Goldman | Sell |
| 2019-07-12 | Aggiornamento | Stifel | Hold → Buy |
| 2019-07-08 | Iniziato | Canaccord Genuity | Buy |
| 2019-03-13 | Iniziato | Ladenburg Thalmann | Buy |
| 2018-09-07 | Ripresa | Morgan Stanley | Overweight |
| 2018-06-25 | Reiterato | Needham | Buy |
| 2018-06-15 | Reiterato | Needham | Buy |
| 2017-10-30 | Iniziato | BofA/Merrill | Buy |
| 2017-10-30 | Iniziato | Needham | Buy |
Mostra tutto
Rhythm Pharmaceuticals Inc Borsa (RYTM) Ultime notizie
Rhythm Pharmaceuticals, Inc. (RYTM) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release - Yahoo! Finance Canada
Rhythm Pharmaceuticals Inc (RYTM) Valuation: PE, PB & Fair Value Analysis - TradingKey
Rhythm Pharmaceuticals Inc (RYTM) Cash Flow - TradingKey
RYTM Initiated Coverage by JP Morgan -- Rating Overweight with $145 PT - GuruFocus
RYTM|Rhythm Pharmaceuticals Inc|Price:106.150|Chg%:+4.050 - TradingKey
RHYTHM PHARMACEUTICALS INC : JP MORGAN INITIATES COVERAGE WITH OVERWEIGHT RATING; PRICE TARGET $145 - Bitget
Rhythm Pharmaceuticals, Inc. (RYTM) Stock Analysis: Evaluating A Potential 35% Upside - DirectorsTalk Interviews
Rhythm Pharmaceuticals Inc - TradingKey
JPMorgan initiates Rhythm Pharmaceuticals stock at Overweight By Investing.com - Investing.com Canada
Rhythm Pharmaceuticals Inc (RYTM) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Rhythm Pharmaceuticals (RYTM) Q1 2023 Earnings ReportResults, Call & Slides - TipRanks
Rhythm Pharmaceuticals, Inc. Revenue Breakdown – FWB:1RV - TradingView
Rhythm Pharmaceuticals (RYTM) Q3 2023 Earnings ReportResults, Call & Slides - TipRanks
Rhythm Pharmaceuticals (RYTM) Q3 2025 Earnings ReportResults, Call & Slides - TipRanks
Rhythm Pharmaceuticals (RYTM) Q1 2026 Earnings ReportResults, Call & Slides - TipRanks
Rhythm Pharmaceuticals (RYTM) Q4 2024 Earnings ReportResults, Call & Slides - TipRanks
Rhythm Pharmaceuticals (RYTM) Q4 2023 Earnings ReportResults, Call & Slides - TipRanks
Rhythm Pharmaceuticals (RYTM) Q2 2023 Earnings ReportResults, Call & Slides - TipRanks
Rhythm Pharmaceuticals (RYTM) Q1 2025 Earnings ReportResults, Call & Slides - TipRanks
Rhythm Pharmaceuticals (RYTM) Q4 2025 Earnings ReportResults, Call & Slides - TipRanks
Rhythm Pharmaceuticals (RYTM) Q3 2024 Earnings ReportResults, Call & Slides - TipRanks
Rhythm Pharmaceuticals (RYTM) Q1 2024 Earnings ReportResults, Call & Slides - TipRanks
Rhythm Pharmaceuticals (RYTM) Earnings Dates, Call Summary & Reports - TipRanks
Rhythm Pharmaceuticals Inc (RYTM) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Rhythm Pharmaceuticals Inc (RYTM) Q3 2024 Earnings ReportResults, Call & Slides - TipRanks
Rhythm Pharmaceuticals (RYTM) Q2 2024 Earnings ReportResults, Call & Slides - TipRanks
Rhythm Pharmaceuticals, Inc. (RYTM) stock price, news, quote and history - Yahoo Finance UK
Kuehn Law Encourages Investors of Rhythm Pharmaceuticals, Inc. to Contact Law Firm - Morningstar
RYTM stock trades around recent range as Rhythm Pharmaceuticals highlights setmelanotide growth - Ad-hoc-news.de
Rhythm Pharmaceuticals to Report Second Quarter 2026 Financial Results on Tuesday, August 4, 2026 - The Manila Times
Rhythm Pharmaceuticals schedules live Q2 results webcast Aug. 4 - Stock Titan
Price-Driven Insight from (RYTM) for Rule-Based Strategy - Stock Traders Daily
Rhythm Pharmaceuticals, Inc. (RYTM) Investor Outlook: Strong Buy Ratings Signal Potential 31% Upside - DirectorsTalk Interviews
Rhythm Pharmaceuticals Inc at Bank of America Global Healthcare Conference Transcript - GuruFocus
Rhythm Pharmaceuticals Inc to Discuss Interim Six-Month Phase 2 Results Evaluating Setmelanotide Call Transcript - GuruFocus
Law firm probes Rhythm Pharmaceuticals officers for possible self-dealing harming shareholders - Pluang
Kuehn Law Encourages Investors of Rhythm Pharmaceuticals, Inc. to Contact Law Firm - GlobeNewswire Inc.
Wells Fargo Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Maintains Target Price $155 - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
Enterprise value to revenue forward of Rhythm Pharmaceuticals, Inc. – BMV:RYTM - TradingView
Does NEJM-Validated TRANSCEND Data on Setmelanotide Reshape the Bull Case for Rhythm Pharmaceuticals (RYTM)? - Sahm
Rhythm Pharmaceuticals (RYTM) Edges Higher, Nears Key Resistance LevelSymmetrical Triangle - dars.gov.et
Citizens reiterates Rhythm Pharmaceuticals stock rating on strong Imcivree launch data - Investing.com Canada
Rhythm Pharmaceuticals, Inc. (RYTM) Stock Analysis: Exploring a 28.91% Upside Potential in Biotechnology - DirectorsTalk Interviews
Enterprise value to EBITDA forward of Rhythm Pharmaceuticals, Inc. – NASDAQ:RYTM - TradingView
Price to earnings forward of Rhythm Pharmaceuticals, Inc. – NASDAQ:RYTM - TradingView
Enterprise value to revenue forward of Rhythm Pharmaceuticals, Inc. – XETR:1RV - TradingView
Analysts Offer Insights on Healthcare Companies: Rhythm Pharmaceuticals (RYTM) and Travere Therapeutics (TVTX) - The Globe and Mail
Rhythm Pharmaceuticals Inc. announced that the results of its Phase 3 Transcend clinical trial for acquired hypothalamic obesity have been published in the top international medical journal, The New England Journal of Medicine. - Bitget
Rhythm Pharmaceuticals Announces NEJM Publication of Phase 3 TRANSCEND Trial Results for Setmelanotide in Acquired Hypothalamic Obesity - Quiver Quantitative
Rhythm Pharmaceuticals Announces The New England Journal of - GlobeNewswire
Rhythm Pharmaceuticals Inc Azioni (RYTM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Rhythm Pharmaceuticals Inc Azioni (RYTM) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| TETRAULT LYNN A. | Director |
Jun 22 '26 |
Sale |
100.32 |
37,000 |
3,711,896 |
7,000 |
1.84%
0.86%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):